Jan 13 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Constellation Brands, Merck and WD-40 on Monday.
HIGHLIGHTS
* Constellation Brands Inc STZ.N: JP Morgan cuts to neutral from overweight |
* Intellia Therapeutics Inc NTLA.O: Jefferies cuts target price to $86 from $128 |
* Merck & Co Inc MRK.N: Leerink Partners cuts target price to $119 from $136 |
* Ultragenyx Pharmaceutical Inc RARE.O: Piper Sandler raises target to $140 from $135 |
* WD-40 Co WDFC.O: Jefferies cuts target price to $270 from $280 |
Following is a summary of research actions on U.S. companies reported by Reuters on Monday. Stock entries are in alphabetical order.
* Advanced Micro Devices AMD.O: TD Cowen cuts target price to $150 from $185 |
* Constellation Brands Inc STZ.N: JP Morgan cuts target price to $203 from $262 |
* Constellation Brands Inc STZ.N: JP Morgan cuts to neutral from overweight |
* Douglas Emmett Inc DEI.N: Piper Sandler raises to overweight from neutral |
* Exelixis Inc EXEL.O: Piper Sandler raises target price to $37 from $36 |
* IGM Biosciences Inc IGMS.O: JP Morgan raises to neutral from underweight |
* Intellia Therapeutics Inc NTLA.O: Jefferies cuts target price to $86 from $128 |
* Intellia Therapeutics Inc NTLA.O: Oppenheimer cuts target price to $40 from $60 |
* Legalzoom.com Inc LZ.O: JP Morgan raises target price to $9 from $8 |
* Legalzoom.com Inc LZ.O: JP Morgan raises to overweight from underweight |
* Merck & Co Inc MRK.N: Leerink Partners cuts target price to $119 from $136 |
* Neogenomics Inc NEO.O: BTIG cuts target price to $18 from $21 |
* Quanterix Corp QTRX.O: TD Cowen cuts target price to $11 from $15 |
* Ultragenyx Pharmaceutical Inc RARE.O: Piper Sandler raises target to $140 from $135 |
* Verona pharma Plc VRNA.O: Jefferies raises target price to $70 from $50 |
* Walgreens WBA.O: TD Cowen raises target price to $15 from $14 |
* WD-40 Co WDFC.O: Jefferies cuts target price to $270 from $280 |
(Compiled by Bengaluru Newsroom)
((Diaries@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。